ARCHIVES

FDA Approves Ribavirin Phase 102 Trials

This article is from The Cancer Letter archive.

Vol. 13 No. 42 | October 30, 1987

Download PDF Visit The Full Archive

Related Articles

Studies Link Age-Dependent Outcome To Immune Cells

November 28, 2003

In Brief: Gene Therapy Pioneer Michael Blaese To Leave NIH For Biotechnology Firm

January 16, 1998

DCT Board Says RDOG Concept Too Expensive; Discusses Grant Funding

July 24, 1992

Clinical Trials: Phase I Trial of Karenitecin Begins, BioNumerik Says

March 5, 1999

FCRF Contracts Hit $40.3 Million With Transfer Of Labs From NIH, Elsewhere

October 8, 1982

AACR Journal Publishes a Henschke Letter Without Disclosure of Conflicts.

April 25, 2008